Aug 12, 2026·Score 81·Type B — Growth-style analysisUsed for higher-growth companies — weighs revenue trajectory, total addressable market (TAM) expansion, and forward-looking multiples.Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$114.46
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$95.00($90.00–$100.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$152.25
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type B - Corcept Therapeutics Incorporated (CORT) 20260812 Stock Analysis
📅 Corcept Key Upcoming Events
October 28, 2026Q3 2026 Earnings Release (Estimated)
Description: The institutional investment community will scrutinize this quarter for the initial sales ramp trajectory of Lifyorli following its March approval, as well as any continued momentum in the core Cushing’s syndrome franchise driven by the CATALYST trial’s widespread diabetes screening initiatives.
December 17, 2026FDA PDUFA Date for Relacorilant in Cushing’s Syndrome (Confirmed)
Description: A critical regulatory milestone following the unexpected December 2025 Complete Response Letter (CRL). An approval here would allow management to seamlessly transition the legacy Korlym revenue base to a superior, proprietary next-generation asset, effectively neutralizing looming generic threats and resetting the endocrine exclusivity clock to 2033.
🏢 Step 1: Corcept Company Overview & Business Model
Q1-A1. What is Corcept?
Company Name (Ticker): Corcept Therapeutics Incorporated (CORT)
Sector: Healthcare
Exchange: NASDAQ
Founded: May 13, 1998
Listing Date: April 15, 2004
Fiscal Year End: December
Headquarters: United States, Redwood City
CEO: Joseph K. Belanoff, M.D. ※ Founder status: Y
Market Cap: $12.35B
Shares Outstanding: 108.10M
Current Price:$114.46
Annual Dividend Yield: ➖ Not applicable
Ex-dividend Date: ➖ Not applicable
As-of: August 12, 2026 (ET)
Q1-A2. How Does Corcept Make Money?
Pioneering Cortisol Modulation: Corcept generates highly durable revenue by discovering, developing, and commercializing proprietary medications that selectively modulate the effects of cortisol, the body’s primary stress hormone. The scientific premise rests on the fact that cortisol hyper-activation drives severe metabolic, psychiatric, and oncologic pathogenesis, allowing Corcept to target diverse indications through a unified mechanism of action.
Legacy Cash Cow (Korlym): Historically, the company’s sole revenue engine was Korlym (mifepristone), the first FDA-approved medical treatment for hyperglycemia secondary to endogenous hypercortisolism (Cushing’s syndrome). By targeting adult patients who failed or are ineligible for surgery, Korlym established a highly profitable, recurring revenue stream within a niche orphan disease market, characterized by immense pricing power and inelastic demand.
Oncology Expansion (Lifyorli): As of March 25, 2026, Corcept commercializes Lifyorli (relacorilant), a first-in-class selective glucocorticoid receptor antagonist (SGRA) approved for platinum-resistant ovarian cancer (PROC) in combination with nab-paclitaxel. This monumental regulatory approval transforms Corcept from a single-indication endocrine holding into a high-growth, diversified oncology player targeting a significantly larger patient population.
Specialty Pharmacy Distribution: The company utilizes a highly controlled, direct-to-patient specialty pharmacy distribution network. This closed-loop system ensures high patient compliance rates, optimizes gross-to-net pricing dynamics, and maintains tight control over the supply chain, which is critical for managing orphan drugs that require complex titration.
Q1-A3. Corcept’s Revenue Segments & Core Income Sources
Endocrinology (Cushing’s Syndrome) (≈90%+ of current revenue):
Contribution: Driven almost entirely by Korlym, this segment generated $761.4 million in FY2025 (up 12.8% YoY) and remains the foundational cash generator funding the entirety of the clinical pipeline and corporate share repurchases.
Driver: Growth is currently propelled by heightened physician awareness of hypercortisolism’s true prevalence—largely spurred by Corcept’s landmark CATALYST trial, which revealed that 24% of difficult-to-control Type 2 diabetes patients actually suffer from underlying, undiagnosed hypercortisolism. This effectively pivots Korlym from a rare disease drug into a specialized metabolic intervention.
Oncology (Lifyorli) (Emerging Driver, <10% currently but scaling exponentially):
Contribution: Following its March 2026 approval, Lifyorli represents the immediate future of Corcept’s top-line acceleration and margin expansion.
Driver: Targeting an expanded Total Addressable Market (TAM) of approximately 20,000 women annually in the U.S. alone with PROC, this segment leverages Lifyorli’s unique mechanism of stripping the cortisol shield that solid tumors use to resist chemotherapy and evade cellular apoptosis.
Q1-A4. Who Are Corcept’s Competitors?
Direct Competitors (Endocrinology): Recordati (Signifor/Isturisa), Xeris Biopharma (Recorlev), and Novartis operate in the Cushing’s space. These companies offer steroidogenesis inhibitors or somatostatin analogs, which attempt to lower systemic cortisol production, whereas Corcept’s assets block the receptor directly.
Direct Competitors (Oncology): In the PROC space, Lifyorli competes against standard single-agent chemotherapies, bevacizumab regimens, and targeted therapies like AbbVie’s Elahere (mirvetuximab soravtansine). However, Elahere is restricted to folate receptor alpha-positive tumors, leaving Lifyorli a massive advantage in biomarker-agnostic populations.
Generic Threats: Teva Pharmaceuticals has FDA approval for a generic version of Korlym, triggering intense, ongoing patent litigation. The overarching corporate strategy is to transition the market to the proprietary relacorilant before Teva can execute an “at-risk” generic launch.
Disrupted Victim: Standard chemotherapy monotherapy regimens and legacy endocrine surgical interventions stand to lose significant market share as Corcept provides highly efficacious, oral, medical alternatives that deliver superior overall survival without requiring complex biomarker screening.
Q1-A5. What Problem Does Corcept Solve?
The Glucocorticoid Shield in Solid Tumors: Advanced solid tumors routinely hijack cortisol signaling pathways to suppress apoptosis (programmed cell death), rendering traditional chemotherapies ineffective and creating fatal drug resistance. Lifyorli elegantly solves this by competitively binding to the glucocorticoid receptor, stripping the tumor of its cortisol defense, and re-sensitizing the malignant cells to nab-paclitaxel, ultimately yielding a massive 4.1-month overall survival benefit in PROC.
The Hidden Endocrine Epidemic in Diabetes: Traditional medicine viewed Cushing’s syndrome as an exceedingly rare condition with obvious phenotypical markers. Corcept’s CATALYST trial proved that hypercortisolism is actually a hidden, root-cause driver in 24% of difficult-to-treat Type 2 diabetes cases. Korlym and relacorilant solve this metabolic dysfunction directly at the receptor level, driving profound improvements in HbA1c (reductions up to 2.01%), weight loss, and hypertension where standard GLP-1 receptor agonists and high-dose insulins routinely fail.
Q1-A6. Corcept Key Milestones: Past 12 Months
September 10, 2025FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Platinum-Resistant Ovarian Cancer
Description: The FDA officially accepted the NDA based on the phase 3 ROSELLA trial data, marking the formal beginning of Corcept’s transition into a commercial-stage oncology company and validating the glucocorticoid receptor antagonism thesis in solid tumors.
December 31, 2025Received Complete Response Letter for Relacorilant in Cushing’s Syndrome
Description: In a surprising and detrimental regulatory setback, the FDA requested additional efficacy data for relacorilant in hypercortisolism, citing concerns over the benefit-risk assessment in hypertension endpoints, thereby delaying the planned obsolescence of the off-patent Korlym.
February 19, 2026Federal Circuit Reaffirms Corcept Patent Loss in Teva Case
Description: The appellate court upheld a district court’s finding that Teva’s generic mifepristone did not infringe upon two of Corcept’s method-of-use patents regarding the safe co-administration of Korlym with CYP3A4 inhibitors, keeping the generic threat elevated.
March 25, 2026FDA Approves Lifyorli (relacorilant) Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer
Description: The ultimate validation of the cortisol modulation thesis in oncology. Lifyorli became the first FDA-approved SGRA, backed by a 35% reduction in the risk of death compared to standard chemotherapy alone in the phase 3 ROSELLA trial.
June 17, 2026Corcept Resubmits New Drug Application for Relacorilant in Cushing’s Syndrome
Description: Following rapid negotiations with the FDA, management addressed the CRL concerns, putting the highly anticipated Korlym successor back on a definitive regulatory clock with a December 17, 2026 PDUFA date.
June 23, 2026Presented Positive CATALYST Trial Treatment Phase Data at ADA Scientific Sessions
Description: Topline clinical results confirmed that Korlym drove a massive 1.47% to 2.01% HbA1c reduction in hypercortisolism patients with uncontrolled diabetes, proving the massive commercial viability of mass-screening diabetics for cortisol excess.
July 29, 2026Q2 2026 Earnings Release
Description: Delivered an absolute blowout quarter with $256.1 million in revenue (up 55.3% YoY), driven by surging Korlym demand and the initial Lifyorli launch; management aggressively raised 2026 revenue guidance to $1.1 billion–$1.2 billion, forcing analysts to rapidly update forward models.
Q1-A7. Step 1 Key Takeaways
Step 1 Summary: Corcept is executing a flawless pipeline-in-a-molecule strategy, pivoting a highly profitable endocrine cash cow into a blockbuster oncology franchise. The recent Lifyorli approval and the CATALYST trial’s TAM expansion form a dual-engine hyper-growth narrative, though legal and regulatory hurdles regarding the legacy asset remain critical stress points.
Top 3 Red Flags:
1 The lingering threat of an “at-risk” generic Korlym launch by Teva if patent defenses collapse before the Cushing’s patient base is fully transitioned to relacorilant.
2 Regulatory execution risk surrounding the December 2026 PDUFA for relacorilant in Cushing’s, following the unexpected Complete Response Letter in 2025.
3 High absolute valuation multiples (Forward P/E >54x) leave zero margin for error in the Lifyorli commercial ramp or subsequent pipeline readouts.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 New patient starts and prescription velocity for Lifyorli in the biomarker-agnostic PROC indication.
Intangible Assets (Patents and Exclusivity): Corcept’s moat is structurally reinforced by a dense thicket of method-of-use and composition-of-matter patents. While the core mifepristone molecule is off-patent, Corcept has heavily patented specific dosing regimens, differential diagnostics, and CYP3A4 co-administrations extending to 2037. More importantly, the next-generation asset, relacorilant, enjoys pristine composition-of-matter protection until at least 2033, alongside Orphan Drug Exclusivity in the U.S. and Europe for Cushing’s syndrome.
High Switching Costs: In severe, life-threatening endocrine disorders like hypercortisolism, patients titrated to a stable, efficacious dose of Korlym experience exceptionally high physiological switching costs. Physicians are highly reluctant to alter a functioning hormone-modulation regimen for a generic alternative due to the fragility of adrenal crisis and metabolic destabilization.
First-Mover Advantage in Glucocorticoid Receptor Antagonism (SGRA): Corcept essentially created the SGRA oncology market from scratch. Lifyorli is the first and only FDA-approved agent of its kind. Decades of specialized research into cortisol’s role in tumor evasion give Corcept an insurmountable data and clinical relationship moat that larger biopharma companies cannot simply replicate with capital deployment.
Biomarker-Agnostic Superiority: Unlike competing oncology therapies (e.g., Elahere) that require specific biomarker expression (folate receptor alpha positivity), Lifyorli’s approval is entirely biomarker-agnostic, giving it universal applicability across the PROC patient population and cementing a structural competitive advantage in prescribing velocity.
Q2-A2. How Big Is Corcept’s Market? (TAM)
Oncology (Platinum-Resistant Ovarian Cancer): Approximately 20,000 women annually in the U.S., and an equal number in Europe, require new therapies for PROC. At standard oncology pricing dynamics, this represents an immediate, multi-billion dollar TAM for Lifyorli.
Endocrinology (The CATALYST Expansion): Previously, Cushing’s syndrome was viewed as an ultra-orphan market of roughly 10,000 to 20,000 U.S. patients. However, the rigorous CATALYST trial established that 24% of difficult-to-control Type 2 diabetics (patients failing three or more medications including insulin and GLP-1s) possess underlying hypercortisolism. With millions of uncontrolled diabetics in the U.S., this mathematically expands Corcept’s endocrine TAM from hundreds of millions to a potential peak exceeding $5 billion.
Upside Potential: The market is currently pricing Corcept at a $12.35B market cap. If Lifyorli scales across multiple solid tumors (prostate, pancreatic, endometrial) currently in Phase 3 trials, and the diabetic hypercortisolism market unlocks, the theoretical TAM easily exceeds $10B annually, offering massive Room to Grow.
Q2-A3. How Real Is Corcept’s TAM? (Quality Check)
Willingness to Pay (WTP): Exceptionally high. Oncology treatments offering a 4.1-month absolute overall survival benefit (a 35% reduction in risk of death) in a refractory setting command premium, inelastic pricing. Similarly, endocrinology drugs for life-threatening hypercortisolism enjoy broad payer coverage and minimal price pushback due to the severity of the untreated disease.
Market Structure: The PROC market was previously fragmented with low-efficacy chemotherapies yielding dismal survival rates. Lifyorli’s introduction, supported by rapid NCCN Guidelines inclusion as a preferred regimen, creates a winner-takes-most dynamic in the second- and third-line settings.
Regulation/Entry Barriers: Extremely high. Developing SGRAs requires highly specialized clinical trial designs and an intricate understanding of cortisol feedback loops and adrenal sufficiency. Competitors attempting to enter the cortisol-modulation space face steep regulatory barriers and years of clinical trial lag, insulating Corcept’s margins.
Q2-A4. Can Corcept Keep Expanding Its Market?
Pipeline-in-a-Molecule Scalability: Relacorilant is not a single-trick asset. Because cortisol suppression of cellular apoptosis is a universal tumor defense mechanism, the biological scalability is theoretically infinite across solid tumors. Corcept is actively running advanced trials combining relacorilant with PD-1 inhibitors and other chemotherapies across prostate, pancreatic, and endometrial cancers.
Zero Marginal Cost Leverage: While it is a pharmaceutical manufacturer, Corcept’s asset-light model (outsourced manufacturing, specialized direct-to-patient pharmacy) allows for massive operating leverage. Adding a new oncology indication requires minimal additional CapEx, acting highly similarly to a software platform scaling across new verticals without heavy physical infrastructure investment.
Q2-A5. Step 2 Key Takeaways
Scoring Rationale:
Economic Moat (9/10): Unrivaled first-mover monopoly in SGRA oncology and profound intellectual property protection extending deep into the 2030s for next-gen assets.
Market Size (5/5): The CATALYST trial fundamentally rewrites the endocrine TAM, while PROC offers an immediate multi-billion dollar oncology runway.
Market Quality·Profitability (6/7): Premium pricing power in oncology backed by a 4.1-month OS survival benefit and NCCN guideline inclusion guarantees high WTP.
Market Penetration·Scalability (7/8): Biomarker-agnostic oncology approvals and pipeline-in-a-molecule optionality offer exceptional global replication capabilities across tumor types.
Step 2 Summary: Corcept has constructed a highly durable, dual-engine moat. The transition from a niche endocrine player to a broad-spectrum metabolic and oncology platform unlocks a TAM vastly larger than its current valuation implies, protected by deep scientific and patent barriers.
🚀 Step 3: How Fast Is Corcept Growing? Hyper-Growth Metrics
Q3-A1. How Fast Is Corcept Growing? (Revenue Trajectory)
Revenue Acceleration (J-Curve): FY2025 revenue hit $761.4 million (+12.8% YoY). However, growth has violently accelerated in 2026. Q2 2026 revenue surged to $256.1 million, representing a blistering +55.3% YoY growth rate.
Guidance Explosion: Management aggressively raised full-year 2026 revenue guidance to an astonishing $1.1 billion to $1.2 billion, signaling sustained >45% YoY growth and proving that the Lifyorli launch is vastly outperforming initial Wall Street models. The growth trajectory has shifted from steady compounding to vertical acceleration.
Q3-A2. Corcept’s Key Growth Metrics
Biotech/Drug Platforms: Clinical stage progress in the pipeline and the ability to address unmet needs in target markets.
Corcept has successfully transitioned relacorilant from a pipeline hypothesis to an FDA-approved oncology blockbuster (Lifyorli) in Q1 2026. Furthermore, the pivotal CATALYST trial results effectively act as a massive commercial screening tool, structurally increasing the diagnosis rate of hypercortisolism in the wild. The rapid NCCN guideline inclusion of Lifyorli acts as a direct catalyst for immediate commercial adoption among community oncologists.
Q3-A3. Are Corcept’s Unit Economics Improving?
Gross Margin: Best-in-class. Gross margins routinely sit between 98.2% and 98.4%. Cost of goods sold (COGS) is effectively a rounding error in the financial statements, showcasing pure pharmaceutical pricing power unencumbered by heavy manufacturing costs.
Rule of 40: Corcept obliterates the Rule of 40. Q2 2026 revenue growth (+55.3%) plus free cash flow margin (approx. 12%) yields a score of 67%, indicating a rare, highly coveted balance of top-tier hyper-growth and cash generation.
LTV / CAC: ➖ Not applicable: As a commercial-stage biopharmaceutical company utilizing specialty pharmacy distribution, traditional SaaS LTV/CAC metrics do not apply; however, high patient compliance and orphan-drug pricing yield massive lifetime values per patient.
Q3-A4. Step 3 Key Takeaways
Scoring Rationale:
Revenue Growth Acceleration (11/12): A jaw-dropping +55.3% YoY top-line surge in Q2 2026 confirms the company is entering a steep hyper-growth phase.
Sector-Specific Growth Metrics (9/10): Perfect execution on the Lifyorli clinical and regulatory front, translating a pipeline asset into an FDA-approved, NCCN-preferred standard of care.
Unit Economics·Margin (7/8): Sustaining ≈98% gross margins while accelerating revenue growth above 50% showcases extraordinary underlying profitability and leverage.
Step 3 Summary: Corcept has successfully hit the absolute inflection point of its J-Curve. The acceleration from low double-digit growth in 2025 to >50% in 2026 proves that both the legacy endocrine expansion and the new oncology launch are firing on all cylinders simultaneously.
Margin Trajectory and Scalability: Corcept is already highly profitable, but the operating leverage is expanding dynamically. In Q2 2026, the company generated $43.0 million in net income (a 16.8% net margin), rebounding sharply from increased R&D and SG&A investments made earlier in the cycle to fund the oncology salesforce build-out.
Profit Recovery Phase: The company has decisively entered a margin expansion phase. As the heavy fixed costs of the Lifyorli Phase 3 trials conclude and shift toward scalable commercial sales, the 98% gross margins will increasingly drop straight to the bottom line, driving EPS estimates up by an estimated 146.9% for 2026.
Q4-A2. Does Corcept Generate Free Cash Flow?
FCF Generation Power: Absolutely. In FY2025, Corcept generated $141.8 million in Free Cash Flow. In Q2 2026 alone, the company generated $31.0 million in FCF, proving its ability to harvest cash during a massive launch phase.
Self-Funding and Capital Efficiency: Corcept operates an incredibly asset-light model. FY2025 CapEx was a mere $211,000 against nearly $800M in revenue. The company requires zero external financing to fund growth, evidenced by a pristine balance sheet holding over $515 million in cash and investments with zero long-term debt.
Q4-A3. Step 4 Key Takeaways
Scoring Rationale:
Operating Leverage·Path to Profit (7/8): High net margins (16.8%) are poised to expand further as 98% gross margin revenues from Lifyorli vastly outpace fixed commercial infrastructure costs.
FCF·Capital Efficiency (7/7): Near-zero CapEx requirements allow the company to convert nearly all operating cash flow into free cash flow, fully self-funding aggressive R&D and share buybacks without debt.
Step 4 Summary: Corcept is a cash-printing machine. Its asset-light pharmaceutical model converts its astronomical gross margins directly into robust free cash flow, insulating the company from macro credit shocks and dilutive financing.
Founder-Led: Yes. Joseph K. Belanoff, M.D., is a co-founder and has served as Chief Executive Officer since the company’s inception in 1998.
Vision and Consistency: Belanoff and his executive team have maintained a relentless, multi-decade focus on the biology of cortisol modulation. Their refusal to abandon the SGRA oncology thesis—despite early Wall Street skepticism—has culminated in the approval of Lifyorli and the discovery of the CATALYST TAM expansion.
Guidance Hit Rate: Management has built a sterling reputation for conservative initial guidance followed by aggressive upward revisions, as evidenced by the massive mid-year 2026 raise to $1.1B-$1.2B, completely blindsiding bearish analysts.
Q5-A2. Is Corcept’s Management Aligned With Shareholders?
Skin in the Game: Management holds significant equity, aligning their net worth with long-term shareholder value creation, though recent divestitures warrant scrutiny.
Insider Trading (Words and Actions Match): There has been a notable, persistent trend of recent insider selling. In the trailing 12 months, insiders have collectively sold approximately $64 million more than they bought via options and on-market transactions. Notable recent sales include CFO Atabak Mokari (intent to sell 40,000 shares worth approx. $4.6M in July 2026), Independent Chairman James Wilson (intent to sell 30,000 shares in June 2026), and Chief Development Officer William Guyer ($338K sold in August 2026). While this is frequently tied to scheduled 10b5-1 option expirations and tax obligations following a 170% stock surge, continuous selling during a massive fundamental inflection point introduces a slight optical headwind to the alignment narrative.
Shareholder Returns (Buybacks): Conversely, management aggressively repurchases stock at the corporate level using free cash flow, returning $172.9 million in FY2025 and acquiring $115.4 million of Corcept common stock in Q2 2026 alone. This proves extraordinary corporate confidence in intrinsic value, structurally reducing the float and partially offsetting the optics of individual insider sales.
Q5-A3. Step 5 Key Takeaways
Scoring Rationale:
Founder Management·Vision (8/8): Dr. Belanoff has masterfully steered a 25-year scientific vision into a multi-billion dollar commercial reality, maintaining laser focus on cortisol biology.
Alignment·Accountability (5/7): Aggressive corporate share repurchases demonstrate excellent capital allocation, though persistent net insider selling limits a perfect alignment score.
Step 5 Summary: Founder-led continuity provides strategic stability and deep scientific expertise, though investors must weigh the aggressive corporate buyback program against recent executive share trimming at all-time highs.
⛵ Step 6: Corcept Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Corcept Guidance
Guidance Gap: Management’s recent revenue guidance raise for 2026 to $1.1B–$1.2B heavily front-ran consensus expectations, forcing Wall Street to aggressively scramble to update models. The 2026 EPS consensus estimates were subsequently revised upward by an astonishing 146.9% year-over-year growth rate.
Priced for Perfection? Despite the blowout guidance, the stock trades at a lofty multiple, meaning the market expects flawless, uninterrupted execution of the Lifyorli launch. Any stumble in quarter-over-quarter prescription velocity could trigger a severe, albeit temporary, multiple contraction.
Q6-A2. What Is Corcept’s Short Interest?
Short Selling Indicators: Short interest sits at a moderately elevated 8.74%. This indicates residual skepticism among hedge funds, likely clustered around the ongoing Teva patent litigation regarding Korlym, and doubts about the ultimate trajectory of relacorilant’s regulatory path in Cushing’s following the 2025 CRL.
Institutional Trends: The stock has seen massive momentum, returning +116.9% over a 3-month window and +171.3% over a 6-month window prior to the Q2 2026 earnings release, signaling heavy institutional accumulation as the oncology thesis de-risked and index funds rebalanced.
Q6-A3. Step 6 Key Takeaways
Scoring Rationale:
Consensus vs Guidance (2/3): Management’s blowout guidance forced massive analyst upgrades, but the resulting high expectations leave the stock vulnerable to any minor execution hiccups.
Supply·Short Interest (2/2): Elevated short interest (8.74%) provides excellent fuel for a sustained short squeeze as the Lifyorli revenue beat continues to force bearish capitulation.
Step 6 Summary: Sentiment is incredibly strong, driven by explosive earnings beats and guidance raises. However, the presence of nearly 9% short interest underscores the lingering battle between hyper-growth bulls and patent-cliff bears.
🧨 Step 7: Corcept Catalysts & Price Triggers
Q7-A1. What Could Re-Rate Corcept Stock? (Next 12 Months)
FDA Approval of Relacorilant for Cushing’s (December 17, 2026): Securing FDA approval on the PDUFA date is the single most critical catalyst. This will allow Corcept to seamlessly transition its legacy Korlym patients to a superior, composition-of-matter protected asset, definitively ending the Teva generic threat and securing the endocrine cash cow through 2033+.
Lifyorli European Approval: A positive EMA decision for Lifyorli in PROC will unlock an additional 20,000-patient TAM, triggering immediate ex-U.S. revenue streams or a highly lucrative commercial partnership.
CATALYST Commercial Ramp: As the ADA Scientific Sessions data filters into primary care guidelines, a quantum jump in widespread 1-mg dexamethasone suppression testing among uncontrolled diabetics will act as a structural supercharger for new Korlym/relacorilant prescriptions, driving sustained beats on endocrine revenue.
Q7-A2. Corcept’s Estimate Revision Trend
Estimate Revisions: Analyst revenue and EPS estimates are undergoing violent upward revisions. Consensus 2026 EPS growth estimates stand at +146.9%, followed by +114.6% in 2027, driven by the dual engines of oncology expansion and CATALYST-driven endocrine screening.
Q7-A3. Step 7 Key Takeaways
Scoring Rationale:
Catalyst Strength (3/3): The December 2026 PDUFA for relacorilant in Cushing’s is a binary event that will structurally secure the company’s baseline valuation and extinguish the generic overhang.
Estimated Trend (2/2): Analysts are scrambling to revise EPS estimates upward by over 140% as the reality of Lifyorli’s TAM and margin profile begins to manifest in financial models.
Step 7 Summary: The setup for the next 12 months is exceptionally catalyst-rich. Regulatory de-risking of the core endocrine franchise combined with real-world oncology revenue prints provide continuous upside triggers for institutional buyers.
⚖️ Step 8: Is Corcept Fairly Valued? Valuation Analysis
Scoring Rationale: On an absolute basis, nearly every traditional multiple screams extreme overvaluation. A Forward P/E approaching 55x and an EV/EBITDA near 80x indicate that the market has entirely priced in the flawless execution of the Lifyorli launch and immediate pipeline success.
📌 (1) Axis Q8-A1 Score:-3
Q8-A2. Corcept vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Forward PER is prioritized for profitable biotechnology companies undergoing commercial hyper-growth.
Calculation of peer-to-peer deviation rate: +131.6%
Scoring Rationale: Compared to Neurocrine Biosciences (NBIX), a mature commercial-stage neuroscience and endocrine peer trading at a Forward P/E of 23.61x, Corcept trades at a massive +131.6% premium. This extreme deviation places the stock firmly in the ‘Very Overvalued’ tier relative to its immediate peer group.
📌 (2) Axis Q8-A2 Score:-4
Q8-A3. What Is Corcept Worth in the Future? (Forward Valuation)
Implied Future Multiple: Based on the 2028 consensus EPS estimate of $7.28, the Implied Future P/E Multiple drops aggressively to 15.22x. Similarly, 2027 EPS estimates of $4.35 yield an implied multiple of 25.48x. When anchored against the mature biotech peer average of roughly 20x–25x, Corcept’s 2027 multiple represents fair value, while its 2028 multiple screens as decidedly undervalued, indicating the growth justifies the current price.
Scoring Rationale: The extreme current multiples are a temporary artifact of the transition phase. The explosive +146% and +114% expected EPS growth over the next two years rapidly compresses the valuation, demonstrating that the market’s future expectations are highly rational and arguably conservative given the TAM expansion.
📌 (3) Axis Q8-A3 Score:+1
Q8-A3-1. What Growth Hurdle Does the Market Demand From Corcept? (Forward Valuation Alternative)
Scoring Rationale: (Not applicable)
📌 (3) Axis Q8-A3-1 Score:➖
Q8-A4. Final Valuation Adjustment
Scoring Rationale: The mechanical valuation framework accurately captures the extreme near-term optical premium balanced against the rapid multiple compression of future years. No fundamental paradigm shift warrants an override outside the standard ±5 range, as the oncology transition is already effectively modeled in the forward estimates.
Commentary: The optical valuation is terrifyingly high for a conservative value investor, but growth investors recognize this as a classic “Priced for Perfection” setup transitioning into severe earnings acceleration. The stock carries a heavy valuation penalty today (driving the -6 point deduction), but if management hits the 2027/2028 EPS estimates, the current $114 level will be viewed in hindsight as a structural discount.
Step 8 Summary: Corcept is statistically expensive today, requiring flawless execution of both the Lifyorli launch and the relacorilant Cushing’s approval to justify its premium multiple.
💀 Step 9: What Are the Risks of Corcept? Fatal Risks & Pre-Mortem
Q9-A1. Is Corcept Burning Cash & Diluting Shareholders?
Cash Exhaustion: Absolutely not. The company holds over $515 million in cash and investments, generates robust positive free cash flow, and carries zero long-term debt. The runway is effectively infinite.
Dilution: Conversely, the company is actively reducing the float, executing massive corporate share repurchases ($172.9M in 2025, $115.4M in Q2 2026), functionally increasing the EPS footprint for remaining shareholders.
Q9-A2. Do Competition or Regulation Threaten Corcept?
Intensifying Competition: While targeted oncology therapies exist, Lifyorli’s mechanism of action (stripping the cortisol shield to re-sensitize tumors to chemotherapy) is wholly unique. The primary competition in PROC remains standard, highly toxic, low-efficacy chemotherapy, giving Corcept a pristine competitive landscape devoid of direct SGRA threats.
Regulatory Risk: This is the company’s Achilles’ heel. The unexpected Complete Response Letter (CRL) in December 2025 for relacorilant in Cushing’s syndrome proved that the FDA is scrutinizing the cortisol modulation space intensely. A second rejection on the December 17, 2026 PDUFA date would be catastrophic for the endocrine franchise.
Q9-A3. Corcept Pre-Mortem: What Could Go Wrong?
If the stock drops 70% in 12 months, the narrative will be written as a dual-failure: The FDA issues a second CRL for relacorilant in Cushing’s syndrome, forcing Corcept to rely entirely on the aging Korlym asset just as Teva Pharmaceuticals wins a final patent appeal and floods the market with cheap generic mifepristone. Simultaneously, the Lifyorli launch stalls as oncologists resist adding an SGRA to standard nab-paclitaxel regimens due to unforeseen real-world tolerability issues, destroying the growth thesis.
Q9-A4. Risk Adjustment Score
Reason for Scoring: Corcept’s financial stamina is bulletproof (infinite cash runway, massive FCF). The deduction is entirely attributed to the binary regulatory risk surrounding the December 2026 PDUFA date for the Cushing’s indication and the lingering, albeit delayed, threat of Teva’s generic Korlym litigation.
📊 Risk Adjustment Score:-3 pts
Step 9 Summary: Financial and dilution risks are zero, but the company faces acute, high-stakes regulatory and patent cliffs that must be navigated perfectly to protect its legacy endocrine revenue while the oncology segment scales.
Commentary: The company achieves near-perfect scores in moat durability, margin profile, and revenue acceleration, reflecting its flawless clinical execution in oncology. The final score is constrained primarily by the severe valuation penalty exacted by current trailing multiples, and a moderate risk deduction acknowledging the binary regulatory event in December.
Q10-A2. Should You Buy Corcept? (Recommendation)
Recommendation:Hold
Commentary: The fundamental transformation of the business is breathtaking, but at 54x Forward P/E, the market has already priced in the immediate success of Lifyorli. Investors should hold current positions to capture the 2027 earnings compression upside, while waiting for temporary multiple contraction, a general market pullback, or the clearance of the December PDUFA before initiating new heavy positions.
Q10-A3. Investment Thesis in One Line
Corcept has successfully transformed from a niche endocrine player into a high-growth, highly profitable oncology powerhouse with Lifyorli, though investors must meticulously monitor the binary regulatory approval of relacorilant in Cushing’s syndrome to ensure its foundational cash-cow is protected from generic threats.
Q10-A4. Corcept’s Price Trend & Key Drivers
Stock Price Trend Over the Past 12 Months:Upward 📈
July 29, 2026Massive Q2 2026 Earnings Beat and Guidance Raise
Description: The company annihilated expectations with 55.3% revenue growth and aggressively raised 2026 guidance to $1.1B-$1.2B, confirming that the Lifyorli launch and CATALYST-driven Korlym prescriptions were vastly exceeding market models. ➡ Stock Price Surge
March 25, 2026FDA Approval of Lifyorli in Ovarian Cancer
Description: Securing approval for the first-ever SGRA in oncology validated Corcept’s decades of cortisol research, unlocking a multi-billion dollar TAM and fundamentally re-rating the company from a rare-disease stock to an oncology growth engine. ➡ Stock Price Surge
December 31, 2025FDA Issues CRL for Relacorilant in Cushing’s Syndrome
Description: The unexpected regulatory rejection shocked the market, creating acute fears regarding the longevity of the Korlym franchise and the threat of impending generic competition from Teva. ➡ Stock Price Plunge
Q10-A5. Action Plan
Current Price:$114.46
Buy Zone:$95.00 ($90.00–$100.00)
(1) Calculation of Fundamental Value: At $95.00, the 2027 Forward P/E compresses to roughly 21.8x, effectively matching the baseline multiple of mature biotech peers like Neurocrine Biosciences, providing a strong fundamental margin of safety for entry.
(2) Momentum Premium/Discount Application: Given the violent upward momentum post-Q2 earnings, the stock is overextended technically. We apply a strict discount, demanding a broader market pullback or technical mean-reversion toward the 50-day moving average before initiating heavy capital deployment.
(3) Conclusion: The $90 to $100 band represents the optimal convergence of fundamental peer-valuation alignment and technical support, stripping away the euphoric premium currently attached to the Q2 guidance raise.
Price Target:$152.25
Expected Return:+33.0% (vs. current price)
📍 Select target stock price calculation criteria:
Earnings base (Forward PER) — Corcept is highly profitable and accelerating net income, making Forward PER the most accurate reflection of its compounding intrinsic value.
🧮 Price Target Calculation Formula:
Per share indicator based (Forward PER, P/FCF, etc.): $4.35 × 35.0x = $152.25
Basis for applying the multiple: Mature biotech peer average of 23.6x — 35.0x — a substantial growth premium is applied to the peer anchor to reflect Corcept’s blistering >50% top-line acceleration, near-100% gross margins, and the massive untapped TAM uncovered by the CATALYST trial.
Conditions and timing for reaching price target: Target realization is intrinsically linked to the December 17, 2026, PDUFA date for relacorilant in Cushing’s syndrome; approval immediately de-risks the baseline endocrine revenue, forcing the market to value the oncology segment purely as additive hyper-growth into 2027.
Stop Loss:$80.00 ($75.00–$85.00)
Action trigger upon catalyst achievement:
1 Securing FDA approval for relacorilant in Cushing’s syndrome on December 17
Description: Approval extinguishes the most significant bear thesis (the generic Korlym cliff) and locks in the proprietary endocrine revenue stream through 2033, securing the balance sheet. 👉 Increased Holdings (Buy)
2 First full-quarter Lifyorli sales exceed $75 million
Description: Proves that real-world oncology adoption matches the clinical hype, demonstrating rapid penetration into the 20,000-patient PROC market without tolerability pushback. 👉 Increased Holdings (Buy)
Action trigger upon risk realization:
1 FDA issues a second CRL for relacorilant in Cushing’s syndrome
Description: This catastrophically delays the transition away from Korlym, leaving the company exposed to imminent generic erosion that will drain the cash flow needed to fund the oncology pipeline. 👉 Reduction in Holdings (Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Wait patiently for the $95 Buy Zone. The current 54x P/E multiple is too fragile for conservative capital; risk should be mitigated by buying only if the December PDUFA is successful.
Neutral Investors: Accumulate a starter position at current levels, reserving 60% of the allocated capital to buy heavily on any macroeconomic weakness that drags the stock back below $105.
Aggressive Investors: Sell out-of-the-money put options near the $100 strike to collect premium while waiting for a dip, positioning to ride the Lifyorli revenue surge into 2027.
Long-Term Tenbagger Vision:
A $120B market cap requires Lifyorli and subsequent pipeline assets to become the foundational standard of care across multiple major solid tumors (prostate, pancreatic), while simultaneously capturing 50% of the newly discovered hypercortisolism TAM in the diabetic population, requiring roughly 7-9 years of sustained >25% CAGR.
Tenbagger Reverse Simulation:
Current Market Cap × 10 = $123.5B
Revenue scale required to justify it = $12.0B
Share of TAM required = 40%
Duration at current CAGR = approximately 7 years
🕵️♂️ Deep Dive Analysis
Q1: Is Corcept’s Heavy Reliance on the Legacy Cushing’s Franchise Its Biggest Weakness?
Analysis: For years, the fundamental bear thesis on Corcept was simple: it was a one-trick pony highly vulnerable to a patent cliff. Korlym, the foundational asset driving nearly all of its $761.4M in 2025 revenue, is based on mifepristone, a molecule that has been off-patent for decades. Corcept’s economic moat relied entirely on method-of-use patents, such as diagnostic methods and CYP3A4 co-administration protocols. Teva Pharmaceuticals’ ongoing litigation to launch a generic version highlighted the extreme fragility of this revenue stream. If generic mifepristone were to flood the market before Corcept successfully transitioned patients to a next-generation asset, the cash flow required to fund the expensive oncology pipeline would evaporate overnight.
Judgment:Neutral — Historically, this was a massive structural weakness. However, it is rapidly neutralizing. The March 2026 approval of Lifyorli fundamentally diversifies the revenue base into oncology. Furthermore, if the FDA approves relacorilant for Cushing’s syndrome in December 2026, Corcept will swiftly transition its patient base to a vastly superior, composition-of-matter protected asset (with patents extending to 2033), effectively closing the door on the generic Korlym threat and turning its biggest historical weakness into a fortified fortress.
Q2: Can Corcept’s 54x Forward P/E Be Justified by the Lifyorli Oncology Ramp?
Analysis: A 54.70x Forward P/E is optically terrifying in the biotechnology sector, especially when compared to mature peers like Neurocrine Biosciences, which trades in the low 20s. However, this multiple is a temporary mathematical artifact of Corcept crossing a profitability inflection point. The Q2 2026 earnings proved that revenues are accelerating vertically (+55.3% YoY), forcing management to raise 2026 guidance to $1.1B-$1.2B. Because Lifyorli commands premium oncology pricing and Corcept maintains ≈98% gross margins, incremental revenue falls violently to the bottom line. This operating leverage is exactly why consensus EPS estimates are surging +146% for 2026 and +114% for 2027.
Judgment:Fairly Valued — While stretched in the immediate term, the multiple is justified by the sheer velocity of earnings compression. By 2027, the implied P/E drops to 25.4x, and by 2028, it plummets to 15.2x. The market is not paying for today’s earnings; it is efficiently pricing in the mathematical certainty of margin expansion driven by a multi-billion dollar oncology TAM.
Q3: How Does the Biomarker-Agnostic Profile of Lifyorli Differentiate It From Competing Oncology Assets?
Analysis: The modern oncology space is increasingly fragmented by hyper-specific targeted therapies. For example, competing ovarian cancer treatments like AbbVie’s Elahere (mirvetuximab soravtansine) require patients to test positive for high folate receptor alpha expression. This necessitates complex, time-consuming diagnostic testing before treatment can begin, limiting the addressable patient pool. In stark contrast, Lifyorli’s FDA approval for platinum-resistant ovarian cancer requires zero biomarker selection. Because cortisol’s anti-apoptotic shielding effect is a universal tumor defense mechanism, any patient meeting the prior-line therapy criteria is immediately eligible for the combination with nab-paclitaxel.
Judgment:Positive — The biomarker-agnostic label removes massive commercial friction. Oncologists can prescribe Lifyorli seamlessly without waiting for pathology reports or dealing with restricted patient subpopulations. This structural advantage guarantees rapid market penetration and positions the drug as the default combination therapy alongside nab-paclitaxel in the second- and third-line settings.
Q4: Will the CATALYST Trial Data Fundamentally Shift the Standard of Care in Type 2 Diabetes?
Analysis: Before the CATALYST trial, hypercortisolism was viewed as an ultra-rare endocrine disease presenting with obvious phenotypical markers (moon face, buffalo hump, severe striae). CATALYST rigorously screened 1,057 patients with difficult-to-control Type 2 diabetes—defined as those failing three or more medications, including insulin and GLP-1s—and discovered that a staggering 24% actually suffered from underlying hypercortisolism. When these patients were treated with Korlym, their HbA1c plummeted by up to 2.01%, alongside significant weight loss and waist circumference reduction. This fundamentally changes the treatment paradigm for metabolic dysfunction.
Judgment:Positive — This is a paradigm-shifting revelation. Instead of relying solely on insulin or GLP-1s to treat the symptoms of diabetes, endocrinologists now have a clinical mandate to screen refractory diabetics using a simple 1-mg dexamethasone suppression test to treat the root cause. This instantly expands Corcept’s addressable market from thousands of rare-disease patients to potentially millions of uncontrolled diabetics, ensuring volume growth for years.
Q5: What Are the Long-Term Implications of the Federal Circuit’s Patent Ruling in Favor of Teva?
Analysis: Teva Pharmaceuticals has secured FDA approval for a generic version of Korlym but has been held off the market by Corcept’s aggressive patent litigation. In February 2026, the Federal Circuit affirmed a lower court ruling that Teva’s generic does not infringe two of Corcept’s method-of-use patents regarding the safe co-administration of Korlym with CYP3A4 inhibitors. This loss theoretically clears a major legal hurdle for Teva to launch its generic product “at risk,” which would involve selling the drug while other patent litigation is still pending, risking treble damages if they eventually lose.
Judgment:Negative — This is the most acute risk facing the company’s legacy cash flow. If Teva launches a generic before Corcept secures FDA approval for relacorilant in Cushing’s syndrome, pricing power in the endocrine segment will collapse. Management is in a race against the clock, fighting a legal rearguard action to delay Teva just long enough to reach the December 2026 PDUFA date, at which point they can transition the patient base and render the generic mifepristone threat obsolete.
Q6: Does the December 2025 Complete Response Letter for Relacorilant Expose Fatal Flaws in Corcept’s Endocrine Pipeline?
Analysis: The December 2025 Complete Response Letter (CRL) for relacorilant in Cushing’s syndrome was a significant stumble. The FDA requested additional efficacy data regarding the drug’s impact on hypertension secondary to hypercortisolism, delaying the drug’s launch. This delay extended Corcept’s reliance on the off-patent Korlym, giving competitors like Recordati (Signifor/Isturisa) and Xeris (Recorlev) extra time to encroach on the endocrine market, while simultaneously keeping the window open for Teva’s generic mifepristone litigation.
Judgment:Neutral — While initially damaging to investor sentiment, management’s swift reaction—resubmitting the NDA by June 2026 and securing a December 2026 PDUFA date—has largely contained the fallout. Because Korlym sales actually accelerated during this delay (driving the Q2 2026 revenue blowout), market share erosion did not materialize. If approval is secured in December, the delay will be remembered merely as a minor speed bump rather than a fatal flaw.
Q7: How Sustainable Are Corcept’s 98 Percent Gross Margins as the Company Scales a Global Oncology Salesforce?
Analysis: Corcept has historically operated with a software-like gross margin profile of 98.2% to 98.4%. However, scaling a major oncology drug like Lifyorli requires significant investments in commercial manufacturing scale, global supply chain logistics, and a vast expansion of the specialized oncology salesforce. Investors might legitimately fear that the transition from a niche rare-disease model to a broad oncology footprint could compress these pristine margins.
Judgment:Positive — The gross margin is highly sustainable. Pharmaceutical Cost of Goods Sold (COGS) are inherently minimal, and Lifyorli (like Korlym) is a small-molecule oral therapy, not a highly complex, expensive-to-manufacture biologic or CAR-T cell therapy. While SG&A absolute dollar costs will rise to support the salesforce, the explosive top-line revenue growth will outpace these fixed costs, ensuring that operating margins actually expand over the next 24 months as the business scales.
Q8: What Does the Disconnect Between Heavy Insider Selling and Aggressive Corporate Buybacks Signal to Investors?
Analysis: Over the trailing 12 months, Corcept insiders have aggressively sold stock, offloading approximately $64 million more than they purchased. Notable recent transactions include CFO Atabak Mokari’s intent to sell $4.6 million in shares, and Chief Development Officer William Guyer selling over $300K in August 2026. Conversely, the company itself is aggressively repurchasing stock at the corporate level using free cash flow, returning $172.9 million in FY2025 and acquiring $115.4 million of Corcept common stock in Q2 2026 alone.
Judgment:Neutral — While insider selling is a terrible optical signal, it is heavily counterbalanced by the massive corporate share repurchase program. Insiders are likely executing pre-planned 10b5-1 tax and diversification strategies following a +170% stock run over the past 6 months. As long as corporate free cash flow continues to aggressively retire shares on the open market, structurally reducing the float, the individual insider sales represent noise rather than a fundamental red flag.
Q9: Can the Scientific Mechanism of Glucocorticoid Receptor Antagonism Scale Beyond Ovarian Cancer?
Analysis: The phase 3 ROSELLA trial was an absolute triumph, delivering a 4.1-month overall survival benefit and a 35% reduction in the risk of death for ovarian cancer patients. However, the true value of relacorilant lies in its mechanism of action. Cortisol suppression of apoptosis is not unique to ovarian cancer; it is a fundamental survival pathway for many solid tumors, acting to suppress the immune system and resist cytotoxic chemotherapies. Corcept is already conducting advanced clinical trials combining relacorilant with enzalutamide in prostate cancer and nab-paclitaxel in pancreatic cancer.
Judgment:Positive — The ROSELLA data provides irrefutable clinical proof-of-concept for the entire SGRA oncology thesis. Because the biological mechanism (stripping the tumor’s cortisol shield) is universal, the probability of success in other solid tumors is heavily de-risked. Lifyorli is not a single-indication drug; it is a pipeline-in-a-molecule capable of addressing multiple massive oncology verticals over the next decade.
Q10: What is the Probability and Impact of an “At-Risk” Generic Launch by Teva Prior to Relacorilant’s Endocrine Approval?
Analysis: Teva possesses FDA approval for its generic version of Korlym but has refrained from launching while patent litigation plays out. If Teva were to launch “at risk” (before all patent appeals are exhausted), they could capture significant market share immediately. However, if Corcept eventually prevails in court, Teva would be liable for treble damages—compensating Corcept for three times the lost profits, which could amount to hundreds of millions of dollars given Korlym’s $761M annual run rate.
Judgment:Neutral — An at-risk launch is a high-stakes gamble for Teva. Given the sheer size of the potential damages and the fact that Corcept is aggressively moving to transition patients to relacorilant by early 2027, Teva may calculate that the risk outweighs the short-term reward of a generic launch. The most likely scenario is a continued legal standoff until the December 2026 PDUFA date, at which point Corcept will control its own destiny by transitioning the market to the proprietary relacorilant.